Piramal Pharma (NSE:PPLPHARMA) ROCE %: 3.82% (As of Mar. 2026)


NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
54 GF Score
Price ₹166.72
GF Value ₹175.28
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Piramal Pharma ROCE %?

Piramal Pharma NSE:PPLPHARMA -0.58% 54 ROCE % is 3.82% as of Mar. 2026. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 54/100 and a GF Value™ of ₹175.28 (Fairly Valued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Piramal Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was 3.82%.

Piramal Pharma  (NSE:PPLPHARMA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Piramal Pharma ROCE % Related Terms

Piramal Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma ROCE % Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial 9.59 2.13 5.79 7.32 1.31

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.64 0.24 1.21 -0.15 3.82
NSE:PPLPHARMA
54GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Piramal Pharma ROCE % Calculation

Piramal Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=1647.4/( ( (156775.9 - 37662.7) + (179650.4 - 47582.8) )/ 2 )
=1647.4/( (119113.2+132067.6)/ 2 )
=1647.4/125590.4
=1.31 %

Piramal Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=5039.6/( ( (0 - 0) + (179650.4 - 47582.8) )/ 1 )
=5039.6/( ( 0 + 132067.6 )/ 1 )
=5039.6/132067.6
=3.82 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 3.82% mean?
Piramal Pharma (NSE:PPLPHARMA) has a ROCE % of 3.82% as of Mar. 2026.
Is Piramal Pharma's ROCE % too high?
Piramal Pharma's current ROCE % is 3.82%. The Drug Manufacturers industry median ROCE % is 7.01. Piramal Pharma's value of 3.82% is 45.5% below this industry median. Overall, Piramal Pharma has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's ROCE % compare to ZTS and UTHR?
Piramal Pharma's ROCE % of 3.82% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Piramal Pharma's value of 3.82% is 45.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current ROCE % of 3.82% is 45.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current ROCE % is 3.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹175.28, compared to a current price of ₹166.72 — trading 4.9% below its estimated fair value. The current ROCE % is 3.82% and 45.5% below the Drug Manufacturers industry median of 7.01. Piramal Pharma's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current ROCE % is 3.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued. The current stock price of ₹166.72 is trading 4.9% below its estimated GF Value™ of ₹175.28. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • ROCE %: 3.82%
  • GF Value™: ₹175.28 vs. price of ₹166.72 (4.9% below fair value)
  • GF Score™: 54/100 with 3 warning signs
  • Industry Position: 45.5% below the Drug Manufacturers median

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
54GF Score

Get the complete analysis for NSE:PPLPHARMA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹166.72
Price
₹175.28
GF Value